Romosozumab is a humanised monoclonal antibody developed by Amgen Inc. and UCB Pharma. It was first approved by the U.S. Food and Drug Administration (FDA) on December 9, 2019. Romosozumab was introduced as a treatment option for osteoporosis in postmenopausal women who are at high risk of fractures. 

A 2016 FRAME study is a pivotal phase 3 clinical trial that shows Romosozumab significantly reduces the risk of new vertebral fractures in postmenopausal women with osteoporosis. The study found that Romosozumab decreased the incidence of new vertebral fractures by 73% compared to placebo after 12 months of treatment.

Romosozumab is indicated for the treatment of the following:

• Osteoporosis in postmenopausal women at high risk of fracture
• Osteoporosis in men at high risk of fracture
• Bone density loss and fracture risk reduction in osteoporosis patients

Romosozumab is administered via subcutaneous injection. The recommended dose is 210 mg once a month, given as two separate 105 mg injections in the upper arm, thigh, or abdomen. This monthly dosing regimen helps maintain effective levels of the drug in the body to provide ongoing therapeutic benefits.

Common side effects of Romosozumab include:

• Injection site reactions (pain, redness, swelling)
• Headache
• Musculoskeletal pain

Serious side effects may include:

• Cardiovascular events such as myocardial infarction and stroke
• Severe allergic reactions
• Hypocalcemia (low calcium levels)

Romosozumab carries a warning for potential cardiovascular events. Patients with a history of cardiovascular disease should be closely monitored for signs of heart attack or stroke. Additionally, there is a risk of hypocalcemia, which requires monitoring and appropriate management.

• Monitor cardiovascular health: Watch for increased risk of myocardial infarction, stroke, and cardiovascular death.
• Manage hypocalcemia: Check and correct serum calcium levels before starting treatment and during therapy.
• Prevent osteonecrosis of the jaw (ONJ): Look out for symptoms of ONJ, particularly in patients with poor oral hygiene or those undergoing dental work.
• Check for delayed fracture healing: Observe patients with recent fractures for any signs of delayed healing or nonunion. 
• Watch for allergic reactions: Be alert to symptoms of hypersensitivity reactions and respond appropriately.
• Avoid use during pregnancy and lactation: Do not use in pregnant or breastfeeding women due to potential risks.

Before starting Romosozumab, ensure that patients are well-informed about the potential side effects and the need for regular monitoring. Emphasise the importance of adhering to the monthly injection schedule to achieve optimal therapeutic outcomes. Patients should be advised to report any unusual symptoms, particularly signs of cardiovascular distress or severe allergic reactions, to their healthcare provider immediately.

For more detailed information, consult the latest clinical guidelines and studies available through reputable medical sources.

1. https://www.sciencedirect.com/topics/neuroscience/romosozumab
2. https://www.ncbi.nlm.nih.gov/books/NBK585139/#:~:text=Romosozumab%20is%20a%20humanized%20monoclonal,formation%20while%20suppressing%20bone%20resorption.
3. https://www.ncbi.nlm.nih.gov/books/NBK595381/ 

MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.